SA-13353
SA-13353 has been in phase II clinical trials for the treatment of diabetic macular edema and rheumatoid arthritis. However, this research has been discontinued.
The compound was originally developed by Santen Pharmaceutical, licensed to Ayumi Pharmaceutical in 2015.
General Information
Update Date：2016-04-25
- Drug Name：
- SA-13353
- Research Code：
- DE-096; SA-13353
- Trade Name：
- MOA：
- Tumor necrosis factor (TNF)-alpha inhibitor
- Indication：
- Diabetic macular edema; Rheumatoid arthritis (RA)
- Status：
- Phase Ⅱ (Discontinued)
- Company：
- Santen (Originator) , Ayumi
- Sales：
- ATC Code：
Chemical Structure
Update Date：2015-12-31
|
Molecular Weight | 411.62 | ||||||||||||
| Formula | C26H41N3O | |||||||||||||
| CAS No. | 379262-36-9 (SA-13353); | |||||||||||||
| Chemical Name | Urea, N-pentyl-N'-[3-(4-pyridinyl)propyl]-N-(2-tricyclo[3.3.1.13,7]dec-1-ylethyl)- | |||||||||||||
| SA-13353 （Free Acid/Base）Parameters： | ||||||||||||||
|
||||||||||||||
| *：Calculated by ACD/Labs software V11.02. | ||||||||||||||